Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-11-21
2009-11-03
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S310000, C514S419000, C546S114000, C546S146000, C548S492000
Reexamination Certificate
active
07612089
ABSTRACT:
The present invention is directed to compounds represented by Formula I and pharmaceutically acceptable salts, solvates, hydrates, and prodrugs thereof which are inhibitors of Factor Xa. The present invention is also directed to and intermediates used in making such compounds, pharmaceutical compositions containing such compounds, methods to prevent or treat a number of conditions characterized by undesired thrombosis and methods of inhibiting the coagulation of a blood sample.
REFERENCES:
patent: 4588587 (1986-05-01), Gasic
patent: 5246943 (1993-09-01), Blankley et al.
patent: 2004/0038858 (2004-02-01), Dorsch et al.
patent: 2005/0137230 (2005-06-01), Dorsch et al.
patent: 0798295 (1997-10-01), None
patent: WO 94/13693 (1994-06-01), None
patent: WO 98/28269 (1998-07-01), None
patent: WO 99/10316 (1999-03-01), None
patent: 01/70684 (2001-09-01), None
patent: WO 01/70684 (2001-09-01), None
patent: WO 97/21437 (2002-04-01), None
patent: WO 02/48099 (2002-06-01), None
Charton et al., Tetrahedron Letters, 2001, vol. 42, pp. 7559-7561.
Kazmierski et al., Journal of Organic Chemistry (1994), 59(7), 1789-95.
Berge et al., “Pharmaceutical Salts,”Journal of Pharmaceutical Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
Claeson, “Synthetic Peptides and Peptidomimetics as Substrates and Inhibitors of Thrombin and other Proteases in the Blood Coagulation System”,Blood Coagulation and Fibrinolyisis, 1994, vol. 5, pp. 411-436.
Elödi et al., “Optimization of Conditions for the Catalytic Effect of the Factor IXa-Factor VIII Complex: Probable Role of the Complex in the Amplification of Blood Coagulation”,Thrombosis Research, 1979, vol. 15, pp. 617-629.
Fressinaud et al., “Therapeutic monitoring of Von Willebrand Disease: Interest and Limits of a Platelet Function Analyser at High Shear Rates”,British Journal of Haematology, 1999, vol. 106, No. 3, pp. 777-783.
Hauptmann et al., “Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors”,Thrombosis and Haemostasis, 1990, vol. 63, pp. 220-223.
Hitomi et al., “Inhibitory Effect of New Synthetic Protease Inhibitor (fut-175) on the Coagulation System”,Haemostasis, 1985, vol. 15, pp. 164-168.
Kam et al., “Mechanism Based Isocoumarin Inhibitors for Trypsin and Blood Coagulation Serine Proteases: New Anticoagulants”,Biochemistry, 1988, vol. 27, pp. 2547-2557.
Maugeri, et al., “Transcellular Metabolism of Arachidonic Acid: Increased Platelet Thromboxane Generation in the Presence of Activated Polymorphonuclear Leukocytes”,Blood, 1992, vol. 80, No. 2, pp. 447-451.
Nutt et al., “The Amino Acid sequence of Antistasin, a Potent Inhibitor of Factor Xa Reveals a Repeated Internal Structure”,Journal Biological Chemistry, 1988, vol. 263, No. 21, pp. 10162-10167.
Rocca et al., “Cyclooxygenase-2 Expression is Induced During Human Megakaryopoiesis and Characterizes Newly Formed Platelets”,Proceedings of National Academy of Sciences, 2002, vol. 99, No. 11, pp. 7634-7639.
Sturzebecher et al., “Synthetic Inhibitors of Bovine Factor Xa and Thrombin. Comparison of Their Anticoagulant Efficiency”,Thrombosis Research, 1989, vol. 54, pp. 245-252.
Tidwell et al., “Strategies for Anticoagulation With Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors”,Thrombosis Research, 1980, vol. 19, pp. 339-349.
Turner et al., “p-Amidino Esters as Irreversible Inhibitors of Factor IXa and Xa and Thrombin”,Biochemistry, 1986; vol. 25, pp. 4929-4935.
Valles et al., “Erythrocytes Metabolically Enhance Collagen-Induced Platelet Responsiveness Via Increased Thromboxane Production, Adenosine Diphosphate Release, and Recruitment”,Blood, 1991, vol. 78, No. 1, pp. 154-162.
Wang et al., “Immunological Characterization of Urinary 8-epi-Prostaglandin F2 Alpha Excretion in Man”,Journal of Pharmacolology and Experimental Therapeutics, 1995, vol. 275, No. 1, pp. 94-100.
Wang et al., “Incidence of Aspirin Nonresponsiveness Using the Ultegra Rapid Platelet Function Assay-ASA”,American Journal of Cardioliology, 2003, vol. 92, No. 12, pp. 1492-1494.
Waxman et al., “Tick Anticoagulant peptide (TAP) is a Novel Inhibitor of Blood Coagulation Factor Xa”,Science, 1990; vol. 248, pp. 593-596.
Yin et al., “Antiaggregatory Activity of 8-Epi-Prostaglandin F2 Alpha and Other F-Series Prostanoids and Their Binding to Thromboxane A2/Prostaglandin H2 Receptors in Human Platelets”,The Journal of Pharmacology and Experimental Therapeutics. 1994, vol. 270, No. 3, pp. 1192-1196.
Bauer Shawn
Scarborough Robert M.
Song Yonghong
Wang Shumei
Zhu Bing-Yan
Portola Pharmaceuticals Inc.
Rahmani Niloofar
Seaman D. Margaret
Townsend and Townsend / and Crew LLP
LandOfFree
Tetrahydroisoquinolines as factor Xa inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tetrahydroisoquinolines as factor Xa inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrahydroisoquinolines as factor Xa inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4132824